New fill/finish partnership with BioConnection
provides end-to-end drug product development under 1 contract!
Read the press release
About Us
Our Company
Executive Leadership
Locations
Global Facilities Network
Seattle
Boulder
Longmont
Copenhagen
Heidelberg
Milan
Chiba
Our Services
Offerings
Mammalian
Microbial
pDNA
Viral Vectors
Cell Therapy
mRNA
Specialized Platforms & Programs
AGCellerate™
BravoAAV™
ProntoLVV™
Proveo™
Services
Tech Transfer
Process Development
Cell Line Development
Analytical & Formulation Development
Process Validation
cGMP Manufacturing
Quality Systems & Inspection Management
Fill & Finish
News & Resources
News & Blogs
Press Releases
Biopharma Thought Leadership Blog
Events & Conferences
Resources
Resources & Scientific Content
Fact Sheets
Case Studies
Video Library
Media Kit
Careers
Career Opportunities
Life at a CDMO
Diversity, Equity & Inclusion
Seattle Team
Boulder Team
Copenhagen Team
Heidelberg Team
Milan Team
Chiba Team
Search
Search
Toggle Menu
Search
Search
Toggle Menu
About Us
Toggle Menu
Our Company
Executive Leadership
Locations
Toggle Menu
Global Facilities Network
Seattle
Boulder
Longmont
Copenhagen
Heidelberg
Milan
Chiba
Our Services
Toggle Menu
Offerings
Toggle Menu
Mammalian
Microbial
pDNA
Viral Vectors
Cell Therapy
mRNA
Specialized Platforms & Programs
Toggle Menu
AGCellerate™
BravoAAV™
ProntoLVV™
Proveo™
Services
Toggle Menu
Tech Transfer
Process Development
Cell Line Development
Analytical & Formulation Development
Process Validation
cGMP Manufacturing
Quality Systems & Inspection Management
Fill & Finish
News & Resources
Toggle Menu
News & Blogs
Toggle Menu
Press Releases
Biopharma Thought Leadership Blog
Events & Conferences
Resources
Toggle Menu
Resources & Scientific Content
Fact Sheets
Case Studies
Video Library
Media Kit
Careers
Toggle Menu
Career Opportunities
Life at a CDMO
Diversity, Equity & Inclusion
Seattle Team
Boulder Team
Copenhagen Team
Heidelberg Team
Milan Team
Chiba Team
Our Company
About Us
Our History
Mission & Values
Executive Leadership
Locations
Global Facilities Network
Seattle
Boulder
Longmont
Copenhagen
Heidelberg
Milan
Chiba
Policies
Environment, Health & Safety
Group Privacy Policies
Offerings
Mammalian
Microbial
pDNA
Viral Vectors
Cell Therapy
mRNA
Services
Tech Transfer
Process Development
Cell Line Development
Analytical & Formulation Development
Process Validation
cGMP Manufacturing
Quality Systems & Inspection Management
Fill & Finish Services
Specialized Platforms & Programs
AGCellerate™ mAb & LVV Programs
ProntoLVV™ Lentiviral Vector Platform
BravoAAV™ Adeno-Associated Vector Platform
Proveo™ ADC Program
News & Blogs
Press Releases
Biopharma Thought Leadership Blog
Events & Conferences
Resources
Research & Scientific Content
Fact Sheets
Case Studies
Video Library
Media Kit
Fact Sheet Quick Links
Global cGMP Manufacturing (PDF)
CHEF1
TM
Expression Technology (PDF)
Mammalian Capabilities (PDF)
Microbial Capabilities (PDF)
Cell Therapy Capabilities (PDF)
Viral Vector Capabilities (PDF)
Plasmid DNA Capabilities (PDF)
Messenger RNA Capabilities (PDF)
Join Us
Career Opportunities
What Drives Us
Life at a CDMO
Diversity, Equity and Inclusion
Meet Our Teams
Seattle
Boulder
Copenhagen
Heidelberg
Milan
Chiba
AGC Biologics Plasmid Production
AGC Biologics
March 16, 2020 at 1:58 PM
Press Release
Tweet
AGC Biologics Appoints Alberto Santagostino as new Chief Executive Officer
October 28, 2024 at 3:00 AM
Press Release
AGC Biologics Seattle Achieves Approval for all 2024 Biologics License Applications from U.S. Food and Drug Administration, Concluding Pre-License Inspection
October 17, 2024 at 3:00 AM
Press Release
AGC Biologics Begins Operations at New State-of-the-Art Manufacturing Building in Copenhagen after Successful Inspection and Licensing from Danish Medicines Agency
October 9, 2024 at 11:00 PM
Press Release
